Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event will feature a fireside chat with Dennis McGrath, Lucid's Chief Financial Officer, scheduled for Tuesday, October 15, 2024, at 11:30 AM Eastern Time.

Interested parties can attend the virtual fireside chat by visiting the provided link. Following the conference, a recording of the session will be available on Lucid's investor relations website. This participation demonstrates Lucid's commitment to engaging with investors and sharing insights about their cancer prevention diagnostics business.

News Market Reaction

+0.70%

1 alert

+0.70% News Effect

On the day this news was published, LUCD gained 0.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim Healthcare Virtual Summit.

Event Details:

• Date: Tuesday, October 15, 2024
• Time: 11:30 AM Eastern Time
• Format: Fireside Chat with Dennis McGrath, Lucid's Chief Financial Officer
• Venue: Virtual

For more information about the 2024 Maxim Healthcare Virtual Summit and to attend Lucid's fireside chat, please visit https://m-vest.com/events/healthcare-10152024. 

A recording of the fireside chat will be made available on the investor relations section of the Company's website at ir.luciddx.com following the conclusion of the conference.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-302271379.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) participating in the 2024 Maxim Healthcare Virtual Summit?

Lucid Diagnostics (LUCD) is participating in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024, at 11:30 AM Eastern Time.

Who will represent Lucid Diagnostics (LUCD) at the 2024 Maxim Healthcare Virtual Summit?

Dennis McGrath, Lucid Diagnostics' Chief Financial Officer, will represent the company in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

How can investors attend Lucid Diagnostics' (LUCD) fireside chat at the 2024 Maxim Healthcare Virtual Summit?

Investors can attend Lucid Diagnostics' fireside chat by visiting https://m-vest.com/events/healthcare-10152024. The event is virtual, allowing for remote participation.

Will there be a recording available of Lucid Diagnostics' (LUCD) presentation at the 2024 Maxim Healthcare Virtual Summit?

Yes, a recording of Lucid Diagnostics' fireside chat will be made available on the investor relations section of the company's website at ir.luciddx.com after the conference concludes.